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Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease 
characterized by the degeneration of motor neurons. Though many molecular and 
genetic causes are thought to serve as predisposing or disease propagating factors, the 
underlying pathogenesis of the disease is not known. Recent discoveries have demon-
strated the presence of inflammation propagating substrates in the central nervous 
system of patients afflicted with ALS. Over the past decade, this hypothesis has incited 
an effort to better understand the role of the immune system in ALS and has led to the 
trial of several potential immune-modulating therapies. Here, we briefly review advances 
in the role of such therapies. The clinical trials discussed here are currently ongoing or 
have been concluded at the time of writing.
Keywords: amyotrophic lateral sclerosis, immunotherapy, microglial activation, neuroinflammation, SOD1
iNTRODUCTiON
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the 
dysfunction and loss of motor neurons in the brain and/or spinal cord. The striking clinical hetero-
geneity seen in ALS implies that a single molecular mechanism is unlikely to be responsible for the 
onset of the disease. The underlying pathophysiology of ALS is not well understood or characterized 
to date. The presence of pro-inflammatory markers in those demonstrating symptoms has been 
recognized but the optimal way to modulate this cause of (and response to) neuronal injury remains 
to be established.
In ALS, cardinal disruptors of cellular homeostasis were originally thought to be oxidative stress 
and glutamate-mediated excitotoxicity. More recently, additional pathogenic processes have been 
identified involving protein (metabolism, misfolding, and aggregation), RNA (altered binding), the 
endoplasmic reticulum and vesicular transport (1, 2). It has also become evident that inflammation 
plays a crucial role in mediating neuronal injury and disease progression (3, 4). Thus, targeting the 
immune system would appear to be a more tractable means of slowing the clinical progression of 
the disease.
Here, we present a brief overview of inflammation in the central nervous system (CNS) as 
relevant to ALS, particularly microglial homeostasis (5). We then summarize clinical trials to date 
of immunomodulatory agents based on these recent insights.
The best-studied animal model of ALS replicates a mutation found in familial ALS (fALS), 
superoxide dismutase 1 (SOD1). However, only 10–15% of ALS is familial and SOD1 mutations 
account for just 10–12% of fALS, thus just 1–2% of all ALS in humans (6).
FigURe 1 | Simplified schema of inflammation in amyotrophic lateral sclerosis (ALS). Some of the treatments in this review with relatively ‘specific’ modes of action 
are also shown.
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The most common genetic cause of fALS has been identi-
fied as a six-nucleotide repeat expansion in the C9orf72 gene 
(chromosome 9, open-reading frame 72). No single abnormality 
appears to occur with similar frequency in sALS.
Amyotrophic lateral sclerosis and frontotemporal dementia 
(FTD) are now often said to be the ends of spectrum, pathologi-
cally (7). In the case of ALS-FTD (ALS with FTD), the C9orf72 
expansion appears to account for approximately 40% of familial 
and 5–10% of sporadic cases (8). This appears to have important 
effects on microglia, discussed below.
iMMUNe SYSTeM iN ALS
For much of the twentieth century the CNS was thought to be 
‘immune privileged’ i.e. protected from invasion from inflamma-
tory cells. Activity of the immune system within the CNS is now 
widely accepted.
A lymphatic system lines the dural sinuses and carries 
immune cells and fluid to cervical lymph nodes (9). Microglia, 
closely related to the macrophages found in other organs, reside 
in the CNS. These cells are capable of screening the entire nervous 
system for foreign material every few hours (10). While circu-
lating lymphocytes do not pass through an intact blood–brain 
barrier (BBB), extravasation does occur during periods of inflam-
mation (11). In the discussion below, we refer to proteins with 
their official NCBI names (followed by more common/historical 
nomenclature) (12).
Pro- and Anti-inflammatory immune 
Phenotypes in ALS
Both microglia (M) and T-cells appear to have central roles in 
the pathogenesis of ALS. As in other organs, once activated in 
response to injury or antigen, microglia and helper T-cells (Th) 
differentiate into a pro-inflammatory (classical, M1 and Th1) phe-
notype. Once the inciting event has been dealt with, these cells 
transition to an anti-inflammatory phenotype (‘alternative’, M2 
and Th2). This process appears best suited to acute injury; when 
the pathogenic stimulus cannot be adequately cleared, chronic 
inflammation develops with persistent M1, Th1 activity that can 
cause unintended injury to local tissues.
A crucial element in ‘tipping the balance’ from one state to the 
other, particularly evident in microglia, is the relative activity of 
NOS2 (inducible nitric oxide synthase) vs. ARG1 (arginase 1); 
this is shown in Figure 1. This balance is particularly important 
for microglia, but is also used by other elements of the immune 
system, including T-cells. The expression of NOS2 is increased by 
transcription factor nuclear factor kappa B (NF-κB), expression 
of which is increased by binding of tumor necrosis factor alpha 
(TNFA) to TNF receptor superfamily member 1A (TNFRSF1A). 
TNFA can also have antiapoptotic effects and lead to an increase 
in neurotrophic factors via TNFRSF1B (discussed further below).
Microglia
Like macrophages, microglia become activated via the receptor 
complex CD14 +  toll-like receptor 4 (TLR4) in response to 
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antigens such as lipopolysaccharide, proteins released from dam-
aged cells (including SOD1protein aggregates, beta-amyloid and 
alpha-synuclein), to infiltrative lymphocytes and to signals from 
the humoral (i.e. antibody-mediated) immune system (Figure 2). 
Relative to the macrophages of other tissues, microglia are less 
potent activators of the immune system. This is in part due to 
their lower expression of protein tyrosine phosphatase, receptor 
type C (aka CD45), leukocyte common antigen and the major 
histocompatibility complex (MHC) (13, 14).
The M1 phenotype shows increased expression of pro-inflam-
matory cytokines such as nitric oxide species, TNFA, and the 
interleukins (IL) 1B, IL2, and IL6 (4). Receptors and transmem-
brane proteins involved in antigen presentation are upregulated, 
including MHC class II, CD86 (B7-2, CTLA-4 counter-receptor 
B7.2), and the Fc fragment of IgG receptor III (FCGR3; CD16) 
(15). They also increase production of reactive oxygen species 
(ROS), which are cytotoxic.
M2 microglia secrete anti-inflammatory cytokines such as 
IL4, IL10, IL13, TGFB and ARG1 as well as neurotrophic factors 
such as glial cell line-derived neurotrophic factor, brain-derived 
neurotrophic factor (BDNF), and insulin-like growth factor-1 
(IGF1). IGF1 has the capacity to promote growth and differen-
tiation of ‘neural stem cells’, helping with tissue repair (16, 17). 
Repair is also mediated via angiogenesis and by remodeling of 
the extracellular matrix (18).
Thus, neurodegeneration is facilitated by the lack of neu-
rotrophic growth factors and by the continued production of 
cytotoxic byproducts of a pro-inflammatory response.
One factor favoring the inflammatory phenotype (and contrib-
uting to neuronal vulnerability to inflammation) is the C9orf72 
expansion. This is in a region which functions as an untranslated 
promoter in microglia, but is translated by neurons. Under nor-
mal circumstances, the highest expression levels in the brain are 
found in microglia. With the expansion, production of C9orf 72 
is impaired in microglia, resulting in impairment of endosome/
lysosomal trafficking. When attempting phagocytosis, such cells 
show an increase in ROS and inflammatory cytokines, thought to 
be due to impairment of phagosome/lysosome fusion (19). In neu-
rons, the transcribed C9orf72 RNA and the translation of useless 
dipeptides from the expanded repeat both appear to contribute 
to susceptibility to inflammation and thus degeneration (8).
Helper T-Cells
Th1 cells secrete pro-inflammatory cytokines such as interferon 
gamma (IFNG), IL2 and TNFB (beta); these proteins also pro-
mote the M1 phenotype of nearby microglia/macrophages. Th2, 
like M2 cells, secrete the anti-inflammatory cytokines IL4 and 
IL10; these cytokines also promote the differentiation of micro-
glia/macrophages along M2 lines.
The balance between Th1 and Th2 is influenced heavily by 
regulatory T-cells (Treg). These are marked by CD4 and IL2RA 
(IL2 receptor subunit alpha, CD25). Their development and 
maintenance depend on the transcription factor forkhead box P3 
(FOXP3); so-named as mutations in Drosophila cause develop-
ment of head-like structures at each pole instead of the usual fore/
hind-gut.
FigURe 2 | Triggering of inflammation and the role of inflammation in propagating amyotrophic lateral sclerosis.
TAbLe 1 | Trials of immune-modulating treatments in ALS registered with NCT.
NCT iD SD Agent ra n wks P RCT Outcomes C R
Primary Secondary
Rheumatoid arthritis
01277315 2/11 Anakinra po 18 4 2 N S/T S/T Y (26)
02588677 4/13 Masitinib + riluzole po 394 48 2/3 Y ALSFRS-R VC, QoL Y NA
02469896 11/15 Tocilizumab iv 24 16 2 Y S/T ALSFRS-R, VC N NA
Multiple sclerosis
00326625 7/06 Glatiramer acetate sc 366 52 2 Y ALSFRS-R ttDV Y (38)
01786174 8/13 Fingolimod po 30 8 2 Y ALSFRS-R, VC, FEV1 T-cell subsets Y (47)
02238626 8/14 Ibudilast po 120 26 1b/2a Y S/T, ALSFRS-R VC, MMT, HHD N (51)
02525471 10/15 RNS60 (saline) iv 18 24 1 N S/T ALSFRS-R, VC, HHD N NA
Anti-inflammatory
00355576 7/06 Celecoxib + creatine po 86 26 2 N ALSFRS-R VC, QoL, TGUG Y (59)
‘ALS-specific’
01753076 12/12 Ozanezumab iv 304 48 2 Y ALSFRS-R, OS VC, HHD, QoL Y (63)
01091142 7/10 NP001 (chlorite) iv 32 26 1 N S/T Biomarkers Y (66)
01281631 2/11 NP001 iv 136 39 2 Y ALSFRS-R VC, TTT, serum IM Y (67)
02794857 8/16 NP001 iv 120 26 2 Y ALSFRS-R TTT, serum IM N NA
Treatment of cancer
00140452 2/05 Thalidomide po 18 39 2 N ALSFRS S/T, QoL, serum IM Y (69)
01257581 3/11 Tamoxifen po 60 42 2 N ALSFRS-R VC, TTT, HHD, ATLIS Y (73)
00397423 12/06 Granulocyte colony-stimulating factor 
(G-CSF)
sc 40 52 2 Y ALSFRS AARS Y (75)
01825551 11/12 G-CSF sc 40 13 2/3 Y ALSFRS-R CMAP, MMT, ALSAQ-40 Y (76)
03085706 10/10 Peripheral blood mononuclear cell 
autotransplantation
sa 14 12 1/2 N S Functional independence, 
balance, dysarthria
Y NA
02286011 11/14 Bone-marrow mononuclear cells im 20 104 1 N S MUNE, CMAP, MRC N NA
Transplant rejection
01884571 10/13 Basiliximab, mycophenolate, tacrolimus, 
methylprednisolone, prednisone
iv, 
po
33 52 2 N ALSFRS-R VC, HHD, serum IM, CSF IM Y NA
ALS, amyotrophic lateral sclerosis; NCT ID, NIH Clinical Trials identifier; SD, start date (month/year); ra, route of administration; po, oral; iv, intravenous; sc, subcutaneous; sa, 
subarachnoid space (i.e., into CSF); im, intramuscular; n, number of subjects; wks, duration of trial (weeks); P, Phase (1–3); RCT, randomized, double-blind, placebo-controlled trial? 
C, completed? (at time of writing); R, reference; NA, not applicable (no results reported yet).
Outcomes—note not all secondary outcomes are listed, for reasons of space.
S, safety; T, tolerability; ALSFRS-R, ALS Functional Rating Scale (revised); VC, vital capacity (any method); FEV1, forced expiratory volume in 1 sec; OS, overall survival; QoL, quality 
of life; ttDV, time to death or ventillator-dependence; MMT, manual muscle testing; HHD, hand-held dynamometry (muscle strength); TGUG, timed get-up-and-go (sitting to walking); 
TTT, time to tracheostomy; IM, inflammatory markers; ATLIS, accurate test of limb isometric strength; AARS, Appel ALS Rating Scale; CMAP, compound muscle action potential; 
ALSAQ-40, ALS Assessment Questionnaire-40; MUNE, motor units estimate (number of motor units); MRC, Medical Research Council (score, muscle strength).
4
Khalid et al. Immunotherapy for ALS
Frontiers in Neurology | www.frontiersin.org September 2017 | Volume 8 | Article 486
Regulatory T-cells encourage M2 differentiation and impede 
the activity of cytotoxic T-lymphocytes (Tc, including natural 
killer T-cells). Lower circulating levels of Tregs have been shown 
in those with ALS vs. controls (20). Lower levels of Tregs and of 
FOXP3 have also been correlated with the rate of clinical progres-
sion of ALS and may be a useful prognostic biomarker that could 
be used to stratify groups in clinical trials (21).
CLiNiCAL TRiALS
Search Methods
We searched the NIH’s ClinicalTrials.gov (NCT), a database of 
medical studies in human volunteers, with the term “amyotrophic 
lateral sclerosis” for any trials focused on modifying inflamma-
tion. We included trials currently in progress or completed prior 
to the time of writing. These trials are summarized in Table 1, 
where they appear in the same order as the treatments discussed 
below. We classified these treatments based on their use in 
other pro-inflammatory diseases. They are sorted (broadly) by 
treatment and by the year the trial began accrual. Some trials 
are discussed here which were not registered with NCT. Also, 
some NCT-registered trials do not yet have a corresponding 
article reporting results and are referenced here with their NCT 
identifier.
Measures of Outcome
The most commonly used measure of outcome in these trials is 
the change in the ALS Functional Rating Scale (ALSFRS) over 
time. In 1999, the scale was revised to include assessments of 
dyspnea, orthopnea, and the need for ventilatory support. This 
latter, the ALSFRS (revised) (ALSFRS-R) has been adopted by the 
majority of clinical investigators since (22). Due to the restrictive 
effect of ALS on pulmonary function, forced vital capacity (FVC) 
is also often used as a measure of disease progression.
DRUgS USeD FOR RHeUMATOiD 
ARTHRiTiS
Rheumatoid arthritis (RA) has been noted with a greater fre-
quency than would be expected by chance in the families of those 
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affected by ALS (23). In the case of the individual patient, just 
seven cases of co-occurring ALS and RA have been reported to 
date. It is thought that most if not all cases were the result of a 
chance association; indeed the coincidence of the two conditions 
would appear to be less than might be expected by chance alone.
Notably, as reported by Padovan et al., in two patients with 
RA, ALS developed rapidly after the introduction of or increase in 
dose of infliximab, a TNFA antagonist (24). While these authors 
acknowledge the limitations of such anecdotal observations, 
this finding would fit with an upregulation of the antiapoptotic 
TNFRSF1B in chronic RA, thereby masking a tendency toward 
ALS in the cases they report. Another case in support of this 
mechanism is that of a patient with psoriatic arthritis who devel-
oped ALS rapidly after starting adalimumab, another antibody 
targeting TNFA (25).
Anakinra
Interleukin 1 is an endogenous pyrogen and a mediator of auto-
immune and infectious diseases (26). Anakinra, a recombinant 
analog of the endogenous antagonist IL1Ra, has already proven 
effective in the treatment of refractory RA (27). IL1R antagonists 
have been shown to extend lifespan in SOD1-G93A mice (28). 
A pilot study of 17 patients treated with anakinra (at the same 
dose used for RA, 100 mg daily) for 1 year showed no significant 
reduction in disease progression, measured with the ALSFRS-R. 
Though the study did show a decrease in cytokines and fibrinogen 
during the initial 24 weeks of treatment, there was a ‘rebound’ 
increase in inflammatory markers during the latter half of the 
study (29).
Masitinib
Masitinib is a pluripotent tyrosine kinase inhibitor which affects 
multiple pro-inflammatory mast cell receptors. It inhibits mast cell 
degranulation and mobility. Studies of masitinib in RA, systemic 
mastocytosis, mast cell tumors and in Alzheimer’s disease have 
already shown promising results. In SOD1-G93A rats, masitinib 
was shown to decrease microglial cell activation via inhibition 
of colony-stimulating factor 1 receptor (30). Masitinib may also 
prevent macrophage infiltration into the ventral root by inhibit-
ing KIT (KIT proto-oncogene receptor tyrosine kinase), thereby 
delaying the ‘dying back’ phenomenon associated with anterior 
horn cell dysfunction (unpublished data, Emilianos Trias et al.).
A Phase 3 randomized, double-blind, placebo-controlled trial 
(RDBPCT) is ongoing to determine the efficacy of riluzole plus 
masitinib vs. placebo in ALS over the course of 48 weeks. The 
interim results are encouraging, with 50% (191 of 381) of patients 
having completed the riluzole and masitinib arm. A statistically 
significant difference was seen in the ALSFRS-R score as well as 
the secondary end points: change in the Combined Assessment 
of Function scale and FVC.
Tocilizumab
Interleukin 6 signaling is major inducer of the acute-phase 
response; its receptor is blocked by the monoclonal antibody 
tocilizumab. Increased serum IL6 is recognized in autoimmune 
diseases such as RA, systemic-onset juvenile chronic arthritis and 
psoriasis as well as patients with sALS. Using peripheral blood 
mononuclear cells (PBMCs i.e. T and B cells as well as mono-
cytes) from four patients with sALS, tocilizumab was shown to 
inhibit the pro-inflammatory effects of adding mutant SOD1-
G93A (31). In particular, the expression of a number of cytokines 
was reduced in vitro: IL6, IL1B, TNFA, IFNG and GM-CSF. A 
Phase 2 RDBPCT investigating the safety and tolerability in adult 
patients with ALS is ongoing. In addition to safety measures, the 
study investigates the effect of tocilizumab on novel biomarkers 
including PBMC gene expression profiles and MRI-PET imaging 
of activated microglia.
DRUgS USeD FOR MULTiPLe  
SCLeROSiS (MS)
Like RA and ALS, MS and ALS appear to aggregate within 
families, while co-occurrence in one individual appears rare. We 
are aware of just four such case reports to date (32). Microglial 
activation appears partly responsible for neuronal injury in both 
ALS and MS (33).
glatiramer Acetate (gA)
Glatiramer acetate is comprised of random polymers of glutamic 
acid (G), lysine (L), alanine (A), and tyrosine (T). It has long been 
used in the treatment of relapsing–remitting MS. In such patients, 
treatment with GA leads to an increase in IL10 and IL4 and a 
decrease in TNFA (34). GA may also increase Treg activity.
The safety of GA in ALS has been demonstrated in a Phase 
1 trial of 20 patients and 10 controls, with doses of 20 mg given 
daily or biweekly to 10 patients each. GA appeared safe and 
encouraging immunological changes were measured (35).
A Phase 2 RDBPCT with 366 patients used GA 40  mg/day 
(vs. ×3/week, as is typical in MS). They remained under observa-
tion for 52 weeks. No significant difference in the rate of deterio-
ration (ALSFRS-R) or overall survival was seen (36). The authors 
speculate that differences in BBB permeability between MS and 
ALS (affecting the pharmacokinetics of GA or the traffic of the 
immune system into the CNS) may account for these results.
Fingolimod
Fingolimod is an inhibitor of the sphingosine 1-phosphate 
receptor (S1PR). This receptor is found on immune cells, 
neural cells, endothelial cells and smooth muscle. It is thought 
to play a role in angiogenesis, neurogenesis and immune 
regulation/trafficking. Inhibition of S1PR causes sequestration 
of lymphocytes within lymph nodes, thereby reducing their 
numbers in the blood stream. It has already proved to be effec-
tive in MS (37).
In SOD1-G93A mice, fingolimod improved survival. Its 
immunomodulatory effects are mediated through NOS2, IL1B, 
FOXP3, IL10, ARG1, integrin subunit alpha M (CD11B, part of 
complement receptor 3) and BDNF (38). An RBDPCT, with 2:1 
randomization, in 30 patients with ALS showed the treatment to 
be safe and tolerable (one patient stopped treatment due to QT 
prolongation) (39). We are not aware of plans to study this agent 
further in ALS.
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ibudilast
Ibudilast is a an inhibitor of TLR4 and phosphodiesterase 3 and 
4 which has shown immunomodulatory effects in MS by shift-
ing the immune response from Th1 to Th2 (40). In ALS, TLR4 
facilitates the transformation of M2 to M1 microglia (41). The 
safety profile of ibudilast has been established through long use 
in the treatment of asthma in Japan. It has been shown to reduce 
the loss of brain volume change in patients with MS (42). A Phase 
2 trial of safety and efficacy in patients with ALS has completed 
accrual and preliminary reports on safety and tolerability are 
encouraging (43).
RNS60
RNS60 is modified saline; it is mixed with oxygen in a controlled 
manner to generate stable, electrically charged nanobubbles. 
This agent is undergoing clinical trials in MS as well as ALS. 
The electrical charge carried by RNS60 affects membrane ion 
channels and increases mitochondrial ATP production in cell 
culture (44, 45). In a mouse model of MS, it has been shown to 
reduce NO and NOS2 production and thus is anti-inflammatory 
(46). This effect is thought to be mediated through the inhibition 
of NF-κB (47). This results in ‘tipping the balance’ toward the 
alternative (M2, Th2) response.
As the drug’s effects are a result of biological and not chemical 
activity, preclinical toxicology studies have shown almost no side 
effects. Safety has been established in three Phase 1 studies, one 
intravenous and two using inhalation. A Phase 1 trial of intrave-
nous RNS60 has completed patient accrual (NCT02525471). This 
will investigate its efficacy as measured by the ALSFRS-R and on 
inflammatory biomarkers.
‘NON-SPeCiFiC’ ANTi-iNFLAMMATORY 
AgeNTS
intravenous immunoglobulin (ivig)
Two small ‘pilot’ studies to assess the effects of a 3-month course 
of ivIg on the severity of ALS have proved disappointing; this 
appears to have put an end to investigation of this modality. 
These studies were performed prior to the advent of the ALSFRS; 
instead, participants served as their own controls.
The first in nine patients with ALS used ivIg 2 g/kg monthly 
for 3 months. No change in disease severity was seen using the 
outcome measure of maximum voluntary isometric contraction 
(MVIC), as per the Tufts Quantitative Neuromuscular Evaluation 
system (48). A subsequent study used the same dose and timing 
in combination with cyclophosphamide 1–2 mg/kg/day in seven 
patients over 4–13  months. The rate of deterioration was no 
slower after starting treatment than before, as measured by the 
means of the Medical Research Council (MRC) score for muscle 
strength (10 muscles/limb  =  40 muscles), a clinical scale for 
bulbar function (range 1–5) and the modified Rankin disability 
scale (range 0–5).
Celecoxib
Celecoxib, a cyclooxygenase-2 inhibitor (prostaglandin G/H 
synthase) is used to treat pain and inflammation; it also decreases 
the prostaglandin-induced release of glutamate. One RDBPCT 
enrolled 30 patients with ALS and randomized their treatment 
(2:1) between celecoxib and placebo for 12 months. No differ-
ence was found in disease progression (ALSFRS-R), muscle 
strength (maximum MVIC), FCV, or in estimates of numbers 
of motor units (49).
Celecoxib has also been evaluated in a Phase 2 adaptive trial. 
Here, it was compared with minocycline; both were given with 
creatine in order to aid mitochondrial function (50). Historical 
controls were used as a comparison. Planned enrollment was with 
sequential pools of 60 patients per arm; after one pool per arm, 
the celecoxib–creatine regimen proved superior to that of mino-
cycline–creatine, although not greatly superior to the historical 
controls, as assessed by the rate of decline in the ALSFRS-R at 
6 months (35).
AgeNTS ‘SPeCiFiC’ TO ALS
Ozanezumab
Activation of the reticulon 4 receptor (RTN4R, aka Nogo recep-
tor) inhibits the growth of axons in mammals following periph-
eral nervous system injury. RTN4R is also found on macrophages, 
where, following Wallerian degeneration, it has been shown to 
mediate the clearance of these cells from the site of injury (51). 
Additionally, RNT4 (Nogo-A) is overexpressed in the skeletal 
muscle of patients with ALS (52).
Thus, ozanezumab (an antibody targeting RNT4) may help 
slow disease progression, either by decreasing the inhibition of 
axonal growth or by affecting the inflammatory process following 
neuronal injury. An RDBPCT with 303 patients tested this treat-
ment, given over 48 weeks. No difference in disease progression 
(ALSFRS-R) or in survival was seen (53). The results are not 
thought to have been due to inadequate dosing or pharmacoki-
netic factors.
NP001
Taurine is an amino acid not incorporated into protein, which 
binds HOCl, as produced by the oxidative burst of activated 
neutrophils. The product of this reaction, taurine chloramine, 
is a less toxic oxidizing agent than HOCl; it is also a signaling 
molecule that contributes to the self-limiting nature of inflamma-
tion. Sodium chlorite (NaClO2; in solution with 63 mM chlorite 
and pH-corrected = NP001, aka WF10) was developed to mimic 
this effect. In PBMCs stimulated by anti-CD3 (part of the T-cell 
receptor complex), WF10 reduced IL2 production as well as the 
nuclear translocation of the transcription factor nuclear factor of 
activated T-cells 1 (NFATC1).
WF10/NP001 was originally developed for advanced-stage 
HIV, to suppress the chronic activation of macrophages, which 
is thought to be partially responsible for neurological injuries 
in HIV (54, 55). It is also being investigated as a treatment for 
MS, although work in ALS is farther along than in these other 
conditions.
A Phase 1 trial in 32 patients showed the treatment to be safe 
and well tolerated (56). There was a dose-dependent decrease in a 
marker of monocyte activation, FCGR3. A subsequent RDBPCT 
with 136 patients showed no effect on ALSFRS-R, although a 
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subset of those with high baseline serum inflammatory markers 
(including IL6, IFNG and CRP) did show stabilization of disease 
(57). A follow-up, focused on those with ALS and high baseline 
CRP, is ongoing.
TReATMeNTS USeD PRiMARiLY  
iN PATieNTS wiTH CANCeR
Thalidomide
Thalidomide is an immunomodulating agent whose effects on 
TNFA have been shown to be beneficial in SOD1-G93A mice 
(58). A trial using 400  mg/day, with outcomes available in 18 
patients, showed no improvement in ALSFRS or FCV vs. historical 
controls. (This dose is similar to that used for refractory chronic 
graft-versus-host disease and to that used in the multi-agent 
treatment of multiple myeloma.) Treatment with thalidomide 
was associated with a number of adverse effects, including deep 
vein thrombosis and bradycardia (59). Bradycardia appears com-
mon, with another study reporting a rate of 50% in 18 patients, 
when used in combination with riluzole (60).
Tamoxifen
A competitive inhibitor of estrogen receptors, tamoxifen 
continues to be used as adjuvant treatment for breast cancer 
as well as endometrial carcinoma. Slowing of ALS progression 
was reported in a woman who started tamoxifen treatment for 
breast cancer at the 2004 International ALS/MND Symposium. 
Its anti-inflammatory effect may result from inhibition of protein 
kinase C (3). A Phase 2 trial in 60 patients reported an increase in 
survival in those using more than 20 mg/day vs. lower doses (61).
Another Phase 2 trial randomized patients to daily creatine 
30 mg or tamoxifen 40 vs. 80 mg. In those taking the higher dose 
of tamoxifen, disease progression was reduced (ALSFRS-R), an 
effect which remained significant after controlling for gender, site 
of disease onset and VC. These results were presented by Atassi 
et al. at the Northeast ALS Consortium Webinar 2013.1
granulocyte Colony-Stimulating Factor 
(g-CSF, Filgrastim)
This compound stimulates the proliferation and differentiation 
of granulocytes; it has been shown to play a part in neuro- and 
angio-genesis as well as modulation of the immune system. It 
is commonly used in myelotoxic chemotherapy to prevent or 
treat neutropenia. In SOD1-G93A mice, use of pegylated G-CSF 
increased survival and reduced microgliosis (62).
A pilot study, with 10 patients available for complete assess-
ment, used a dose of 2 g/kg for 5 days. While the first 3 months of 
showed a significant reduction in the rate of decline (ALSFRS), 
there was a ‘rebound’ worsening in the subsequent 3 months (63). 
The decline in compound muscle action potential (CMAP) was 
also reduced during the first 3 months and remained unchanged 
thereafter.
1 http://vimeo.com/66738855.
An RDBPCT in 10 patients used a dose of 10 μg/kg on days 
1–10 and 20–25 (64). No difference in disease progression at 
100  days (ALSFRS) was noted. There was a smaller decline in 
fractional anisotropy of the brain in the treated group. This MRI 
finding, which measures the ‘directionality’ of water flow, is 
considered a marker of axonal myelination (65).
Based on these encouraging results, a larger RDBPCT was 
performed with 40 patients, using G-CSF at 5 μg/kg/q12h for 
5 days; they were observed for 3 months. There was no change 
in disease progression, as measured with the ALSFRS-R, the 
ALS Assessment Questionnaire-40, manual muscle testing, and 
CMAPs (66). Although the duration of the trial was relatively 
short, the authors note “previous studies suggest that a longer 
duration of follow-up is unlikely to confer any important clinical 
benefit with currently administered doses of G-CSF.” The small 
sample size was based on a large expected difference in the 
change in ALSFRS-R, which may in retrospect have been a 
little optimistic. Another trial of G-CSF in 40 patients appears 
to have been completed, although no results are available 
(NCT00397423).
white blood Cell Support
Isolation of mononuclear cells from blood and bone marrow 
has long been used to provide support for patients undergoing 
myelotoxic chemotherapy or marrow transplantation. Thus, 
such facilities are likely to be available wherever such treatments 
are used.
A single-center, Phase 1 RDBPCT to assess the rate of adverse 
events related to the intramuscular infusion of autologous 
mononuclear cells of bone marrow is currently underway and 
scheduled to complete at the end of 2017 (NCT02286011). A 
similar study was completed to access the deliverance of PBMC 
transplantation into the subarachnoid space, but has not yet 
reported results (NCT03085706).
Another Phase 1 trial with three patients used leukapheresis 
followed by isolation and expansion of Tregs. They received four 
infusions of these Tregs every 2 weeks, with simultaneous subcu-
taneous IL2 (to expand T-cells). This modality appears safe and 
clinical benefits were noted for up to 1 month after the infusions 
were stopped (67).
TReATMeNTS USeD AS PART OF ORgAN 
TRANSPLANTATiON
Cyclosporine
Cyclosporine, which reduces production of IL2, is an oral 
agent which does not appear to cross the intact BBB. When 
infused into the lateral cerebral ventricle of SOD1-G93A mice, 
cyclosporine leads to improved survival (68). An RDBPCT of 74 
patients used variable dosing to achieve a target serum level of 
400–600 ng/mL. This level is slightly higher than that typically 
used after solid organ transplant (100–400  ng/mL). A slower 
rate of progression was seen in men who started to receive treat-
ment within 18 months of symptom onset. However, those who 
entered the study later in the disease course than 18  months 
showed no improvement (69).
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Total Lymphoid irradiation
Irradiating the thymus, spleen and lymph nodes (while shield-
ing non-lymphoid organs) is a treatment used typically in 
preparation for organ transplant and occasionally for severe 
cases of autoimmune diseases such as RA. One RDBPCT with 
61 patients showed no difference, after 2  years observation, in 
muscle strength (via MRC or dynamometer), swallowing (time 
to swallow 4 oz water), walking (time to walk 15 and 25 feet) or 
survival (70).
Prevention of Transplant Rejection
A variety of agents, typically in combination, are used to pre-
vent acute graft-versus-host disease in transplant recipients. 
An observation in ALS patients undergoing neural stem cell 
injections into the spinal cord lead to the hypothesis that the 
immune-suppression required for the injections was, at least in 
part, responsible for the therapeutic effects. A Phase 2 trial with 
33 patients to assess this has been completed (NCT01884571). 
This used basiliximab (anti-IL2) with mycophenolate (an inhibi-
tor of nucleotide synthesis, which T- and B-cells rely upon) and 
tacrolimus (inhibits translocation of NFATC1 and thus transcrip-
tion of IL2, TNFA, IFNG and NOS2 among other effects) as well 
as steroids.
DiSCUSSiON
The majority of the agents we reviewed appear safe and well 
tolerated; many are already in use for other conditions and so 
good information is available regarding side effects and moni-
toring. The most promising approaches identified in our review 
included NP001, masitinib–riluzole, celecoxib–creatine and 
tamoxifen–creatine [(58, 66, 71), NCT02588677]. All of these 
treatments await confirmation in larger RCTs.
As ALS progresses, so does the risk of infection, particularly 
aspiration pneumonia. Also, the part played by ‘tractable/ 
modifiable inflammation’ relative to ‘degeneration’, as a cause 
of clinical disability, is likely to decrease, although this requires 
further investigation. In the case of secondary-progressive MS, 
where this transition has been better studied, CNS inflammation 
does not appear to cease, but becomes more difficult to address 
as much of the inflammation it is ‘hidden’ behind the BBB (72).
Thus, the risk/benefit ratio to immunosuppression in ALS 
is likely to increase with disease progression. A number of the 
treatments above are strongly immune-suppressing and the risk 
of infection associated with such medicines is well recognized 
in treating other autoimmune disorders, particularly in rheu-
matology (71). The risk of cancer with long-term immunosup-
pression in the setting of solid organ transplant has also been 
acknowledged. With a follow-up of 15 years after transplant, the 
sex- and age-standardized incidence ratio (i.e., number of can-
cers observed/number of cancers expected) has been estimated 
at 2.2 (73).
In other inflammatory conditions with progressive disability, 
patients appear willing to accept an early risk of complications 
in return for preventing later disability. In the case of a survey 
of MS patients, in return for approximately 5  years free of 
relapse and disability, patients were willing to accept a risk of 
approximately 1% for each of progressive multifocal leukoen-
cephalopathy, leukemia and liver failure (74). Similar patient 
risk/benefit preferences have not been studied for ALS. Such 
work will likely need to wait for robust estimates for a treatment 
with proven efficacy.
The immune-suppressing treatment with the greatest poten-
tial short-term risk and arguably the greatest prospect of long-
term control remains autologous bone marrow transplantation 
(ABMT). Preliminary experience of safety and efficacy in MS has 
proved encouraging, with transplant-related mortality rates of 
0.3% (349 patients transplanted after 2005) and 0% (119 patients 
treated with a low-intensity regimen) (75). ABMT is not under 
investigation in ALS, to our knowledge.
Many of the drugs discussed above have also proved effective 
in psoriasis, a common inflammatory condition that also injures 
ectoderm-derived cells and is characterized by a chronic Th1 
response, but that has received almost no attention in relation to 
ALS. While psoriasis tends to develop at a far younger age, any 
association (or lack thereof) in an individual or family affected 
by ALS could improve our understanding of both conditions. Of 
course, affecting inflammation within the relatively ‘immune-
privileged’ CNS (vs. skin) has proved to be more challenging, 
in part due to accessibility and differences in pharmacokinetics.
The problem in translating work in mice into trials in humans 
in ALS is well recognized and has been reviewed by Mitsumoto 
et al. (5). SOD1-G93A remains the predominant mouse model. 
Given the rarity of SOD1-G93A as a cause of fLAS, trials con-
ducted in those affected have proved difficult to perform and 
arguably would be limited relevance to sALS. Importantly, this 
mouse model has a different cause than sALS; the latter appears 
to have a variety of predisposing and precipitating factors, all 
of which converge on motor neuron death. This phenomenon, 
whereby a variety of pathological processes converge on a com-
mon phenotype, is also seen in Parkinson’s and (arguably) in 
Alzheimer’s disease. In both conditions, a subtype characterized 
by inflammation (vs. other metabolic abnormalities) has been 
proposed (76, 77). Splitting or stratifying such ‘hot’ vs. ‘cold’ 
disease subtypes appears to be a rational strategy, particularly 
while investigating anti-inflammatory and immune-suppressing 
treatments.
Focusing on the mediators of disease progression (vs. inciting 
mechanisms), particularly the immune system, thus offers the 
promise of treatments which are applicable to a wide range of 
patients with ALS.
Despite these challenges and the number of negative results, 
work by trialists has done much to improve our understanding 
of ALS in untreated patients. The ALS Patient Care Database 
should also prove valuable in this regard (78).
Whether ALS may be said to have a ‘natural history’ is debat-
able, as continuous improvements in supportive care have led to 
better outcomes for those affected. This is particularly true in 
the case of preventing infections, pressure ulcers, malnutrition 
(with feeding via gastrostomy if necessary) and respiratory 
failure (with non-invasive ventilation). Bearing this in mind, 
we hope that a ‘pooled’ cohort of patients receiving placebo as 
part of a clinical trial will become available. Such patients could 
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serve as historical controls for new treatments in early stages 
of development. However, the quality of supportive care would 
need to be accounted for in such a pooled group; as a surrogate, 
the date and location of those receiving placebo on trial could 
be used.
CONCLUSiON
A number of basic science and clinical research studies have 
demonstrated a correlation between the immune system and 
ALS pathology. Despite these findings, the optimal targets have 
yet to be elucidated. It remains to be seen if inflammation is of 
similar importance in all forms of ALS. Improving our knowledge 
of inflammatory biomarkers that correlate with ALS progres-
sion may speed the development of such immune-modulating 
treatments.
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